Evaxion Biotech A/S (EVAX)
| Previous Close | 2.6200 |
| Open | 2.5800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.6200 - 2.6200 |
| 52 Week Range | 2.2600 - 13.6100 |
| Volume | |
| Avg. Volume | 47,756 |
| Market Cap | 14.615M |
| Beta (5Y Monthly) | -0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8000 |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.85 |
GlobeNewswireEvaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include: Significant expan
- Zacks Small Cap Research
EVAX Exceeds Estimates and Confirms Partnership
By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it
